ZOPROL

This brand name is authorized in New Zealand, Turkey

Active ingredients

The drug ZOPROL contains one active pharmaceutical ingredient (API):

1 Lansoprazole
UNII 0K5C5T2QPG - LANSOPRAZOLE

Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid.

Read about Lansoprazole

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A02BC03 Lansoprazole A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BC Proton pump inhibitors
Discover more medicines within A02BC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 9991, 9992
Country: TR ฤฐlaรง ve Tฤฑbbi Cihaz Kurumu Identifier(s): 8699622160258, 8699622160265

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.